Investors rejoice in Celera promise

Article Abstract:

Celera Genomics has announced that it has completed decoding 99% of human genes and finish a human genetic blueprint in 2000. This will allow it to furnish the drug industry and the public with a database which will revolutionize the diagnosis and treatment of disease. Celera's announcement mean that it will complete a human genetic blueprint ahead of the $3-billion, publicly funded Human Genome Project, which is expected to deliver a different type of human genetic blueprint by 2003.

Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Celera Genomics Group

---

New drug targets cancer cells

Article Abstract:

ImClone Systems Inc's new drug, called C225, has been proven to reduce the size of tumors and weaken cancer cells' defense against chemotherapy. In the case of Shannon Kellum, an accountant diagnosed to have metastatic colon cancer, the administration of C225 shrank her tumors by 80% in just four months. Unlike other anticancer drugs, C225 does not destroy healthy cells along with cancer cells.

ImClone Systems Inc.

---

Drugs that starve tumors prove disappointing

Article Abstract:

Anti-angiogenesis agents intended to starve tumors of their blood supply have not produced dramatic cures promised by research and sensationalized in the media. According to Angiogenesis Foundation Pres William Li, over 8,000 cancer patients worldwide have been treated with over 50 anti- angiogeneis agents. However, only a small percentage of the patients have experienced dramatic improvement, with some showing either modest effects or no effects at all, and in some cases patients' conditions have worsened.

Similar abstracts:

• Abstracts: The Monday interview: Lucas has prescription for drug firm mergers. Quebec's drug payment policy hasn't stopped job losses: study
• Abstracts: Just how safe is that catalog in your mailbox? The direct mail industry is working on assurances. The Ad Council, criticized for its response to Sept. 11, moves ahead with plans to remake itself
• Abstracts: It's the Florida law: no state inspectors in big parks. Life in the fast lane. Disney bets on new anaheim 'Adventure'
• Abstracts: As thrills rise, so does debate over ride safety. Fodor's hits the road with a 15-volume series. Premier Cruises goes under
• Abstracts: FDA probe into antibiotic deaths called inadequate. Senator: Lockheed trying $100M scam. Inspector: Defense must reprioritize clearances

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.